Clinical Trial Update: Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial registry update describes the phase 1/2 evaluation of BAFFR CAR T cells for relapsed or refractory Neuromyelitis Optica Spectrum Disorder, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• BAFFR CART (BAFF receptor-targeted CAR T cells)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING